sRAGE as severe acute bronchiolitis biomarker, prospective observational study

Area of Science:

• Pediatric critical care medicine
• Respiratory medicine
• Immunology

Background:

• Acute bronchiolitis (AB) is a common cause of infant hospitalization, with some cases requiring intensive care.
• Identifying infants at high risk for severe AB progression is crucial for timely intervention.
• The soluble receptor for advanced glycation end products (sRAGE) is implicated in immune responses and inflammation.

Purpose of the Study:

• To investigate serum sRAGE levels in infants with severe AB.
• To assess the correlation between serum sRAGE and AB severity, complications, and outcomes.
• To explore the potential role of sRAGE as a biomarker for severe AB.

Main Methods:

• A prospective, observational study involving 52 infants with severe AB admitted to a Pediatric Intensive Care Unit (PICU).
• Serum sRAGE levels were measured and compared to 27 healthy controls.
• Correlations were analyzed with clinical severity scores, causative viruses, respiratory support, and length of stay.

Main Results:

• Serum sRAGE levels were not significantly different between severe AB patients and controls.
• No correlation was found between sRAGE and AB severity, causative viruses, or clinical outcomes.
• Serum sRAGE was higher in patients with lung consolidation and showed a weak positive correlation with C-reactive protein and procalcitonin.

Conclusions:

• Serum sRAGE is not a reliable predictor of AB severity or prognosis in hospitalized infants.
• Elevated sRAGE in the presence of lung consolidation warrants further investigation into the AGE-RAGE axis in AB.
• Additional research is needed to fully elucidate the role of sRAGE in pediatric respiratory infections.